Notably, several studies have found that commonly used tumor biomarkers, such as carcinoembryonic antigen, alpha fetoprotein, glycoantigen 125, glycoantigen 199, and glycoantigen 72-4, exhibit lower sensitivity than ctDNA (Yang et al., 2018). The gene discussed is CEACAM5; the disease is neoplasm.